Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Anna-Lena Illert"'
Autor:
Rieke Schröder, Anna-Lena Illert, Thalia Erbes, Christian Flotho, Michael Lübbert, Jesús Duque-Afonso
Publikováno v:
Epigenetics, Vol 17, Iss 6, Pp 612-624 (2022)
The stage and molecular pathology-dependent prognosis of breast cancer, the limited treatment options for triple-negative carcinomas, as well as the development of resistance to therapies illustrate the need for improved early diagnosis and the devel
Externí odkaz:
https://doaj.org/article/08b4ae20ea1f499792574a5adeaa10a2
Autor:
Susanne Kratzat, Viktoriya Nikolova, Cornelius Miething, Alexander Hoellein, Stephanie Schoeffmann, Oliver Gorka, Elke Pietschmann, Anna-Lena Illert, Jürgen Ruland, Christian Peschel, Jonas Nilsson, Justus Duyster, Ulrich Keller
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e37433 (2012)
The Cks1 component of the SCF(Skp2) complex is necessary for p27(Kip1) ubiquitylation and degradation. Cks1 expression is elevated in various B cell malignancies including Burkitt lymphoma and multiple myeloma. We have previously shown that loss of C
Externí odkaz:
https://doaj.org/article/afe355765585493f97bae702598c6107
Autor:
Albrecht Stenzinger, Robert Thimme, Ambros J. Beer, Oliver Kohlbacher, Anna Wedell, Michael Bitzer, Mikaela Friedman, Mia Wadelius, Thomas Seufferlein, Per Sikora, Peter Kuhn, Thoas Fioretos, Hans Ehrencrona, Stefan Fröhling, Justus Duyster, Anna Lindstrand, Lars Engstrand, Verena I. Gaidzik, Johan Botling, Melanie Boerries, Lucia Cavelier, Anna Lena Illert, Martin Hallbeck, Michael Akhras, Gisela Helenius, Christopher Schroeder, Jan Budczies, Anders Edsjö, Valtteri Wirta, Carolin Ploeger, Silke Lassmann, Erik Melén, Lars Palmqvist, Maréne Landström, Peter Schirmacher, Lovisa Lovmar, Peter Horak, David Gisselsson, Nisar P. Malek, Lars-Åke Levin, Richard Rosenquist, Konstantin Nikolaou
Publikováno v:
Seminars in Cancer Biology. 84:242-254
Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c8cb8495d982ddf55bd8513512b3b78
https://doi.org/10.1016/j.semcancer.2021.05.026
https://doi.org/10.1016/j.semcancer.2021.05.026
Autor:
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia Von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Furstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Publikováno v:
Blood. 140:834-836
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c63b949913b225bafcce0f28c979b60
https://doi.org/10.1182/blood-2022-163245
https://doi.org/10.1182/blood-2022-163245
Autor:
Stefanie Kreutmair, Dietmar Pfeifer, Miguel Waterhouse, Ferenc Takács, Linda Graessel, Konstanze Döhner, Justus Duyster, Anna Lena Illert, Anna-Verena Frey, Michael Schmitt, Michael Lübbert
Publikováno v:
Cancer Immunology, Immunotherapy. 71:2913-2928
Wilms’ tumor 1 (WT1) protein is highly immunogenic and overexpressed in acute myeloid leukemia (AML), consequently ranked as a promising target for novel immunotherapeutic strategies. Here we report our experience of a phase I/II clinical trial (NC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01bac8d1f8f6a882571d1bbc8c6e09a9
https://doi.org/10.1007/s00262-022-03202-8
https://doi.org/10.1007/s00262-022-03202-8
Autor:
Michael Rassner, Silvia Waldeck, Marie Follo, Stefanie Jilg, Ulrike Philipp, Martina Jolic, Julius Wehrle, Philipp J. Jost, Christian Peschel, Anna Lena Illert, Justus Duyster, Florian Scherer, Nikolas von Bubnoff
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 6; Pages: 5411
Background: Mutations in cKIT or PDGFRA are found in up to 90% of patients with gastrointestinal stromal tumors (GISTs). Previously, we described the design, validation, and clinical performance of a digital droplet (dd)PCR assay panel for the detect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20b36aa1e010000c4dc0ebecb820a538
Autor:
Philip Keye, Anne Charlet, Michael Reth, Kathrin Kläsener, Max Kappenstein, Cornelia Endres, Teresa Poggio, Nikolas von Bubnoff, Anna Lena Illert, Jana Sänger, Stefanie Kreutmair, Cornelius Miething, Christoph Rummelt, Justus Duyster, Sivahari P. Gorantla
Publikováno v:
Leukemia. 36:701-711
FLT3-ITD is the most predominant mutation in AML being expressed in about one-third of AML patients and is associated with a poor prognosis. Efforts to better understand FLT3-ITD downstream signaling to possibly improve therapy response are needed. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fb8aa8e0d51349749e9a105ed9eb4bc
https://doi.org/10.1038/s41375-021-01462-4
https://doi.org/10.1038/s41375-021-01462-4
Autor:
Sivahari Prasad Gorantla, Michael Rassner Rassner, Tony Andreas Müller, Teresa Poggio, Kirstyn Anne Crossley, Anna-Lena Denecke, Kornelia R Fritsch, Geoffroy Andrieux, Helen Kleinfelder, Shifa Khaja Saleem, Sudheer Madan Mohan Gambheer, Irene Gonzalez Menendez, Detlef Bentrop, Rainer Trittler, Svetlana Rylova, Dietmar Pfeifer, Leticia Quintanilla Martinez, Christine Dierks, Robert Zeiser, Anna Lena Illert, Nikolas von Bubnoff, Justus Duyster
Publikováno v:
Cancer Research. 83:4497-4497
Ruxolitinib (Jakavi) is a potent JAK1/JAK2 specific inhibitor, approved for the treatment of myeloproliferative neoplasia (MPN) such as primary myelofibrosis (PMF) and polycythemia Vera (PV). The primary clinical benefit of ruxolitinib in MPN patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::857146eb95a92e19978d8b389e12a384
https://doi.org/10.1158/1538-7445.am2023-4497
https://doi.org/10.1158/1538-7445.am2023-4497
Autor:
Michal Kulinski, Annette Schmitt-Graeff, Tony A. Mueller, Christian Peschel, Melanie Boerries, Christine Dierks, Teresa Poggio, Irith Baumann, Justus Duyster, Milena Pantic, Michael L. Cleary, Nina Cabezas-Wallscheid, Khalid Shoumariyeh, Alina Mueller-Rudorf, Bernhard Kuster, Marie Follo, Hiroyuki Kawaguchi, Simone Lemeer, Miriam Erlacher, Detlev Schindler, Martina Rudelius, Anna Lena Illert, Tamina Rückert, Cathrin Klingeberg, Robert A.J. Oostendorp, Rouzanna Istvanffy, Jesus Duque-Afonso, Stefanie Kreutmair, Marcin W. Wlodarski, Charlotte M. Niemeyer, Dietmar Pfeifer, Geoffroy Andrieux, Robert Zeiser, Melissa Zwick
Publikováno v:
The Journal of Clinical Investigation
J Clin Invest
J Clin Invest
Inherited bone marrow failure syndromes (IBMFSs) are a heterogeneous group of disorders characterized by defective hematopoiesis, impaired stem cell function, and cancer susceptibility. Diagnosis of IBMFS presents a major challenge due to the large v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61462e7db1a8cfc0db570d2e0d546864
https://doi.org/10.1172/jci126215
https://doi.org/10.1172/jci126215
Autor:
Martina Fröhlich, Dirk Jäger, Michael Bitzer, Alexander Desuki, Stefan Fröhling, Benedikt Brors, Daniel Hübschmann, Hanno Glimm, S. Heidegger, R.F. Schlenk, Marcus Renner, Sebastian Uhrig, H. Süße, Volker Heinemann, Simon Kreutzfeldt, Arndt Vogel, Christoph E. Heilig, Gustavo B. Baretton, Veronica Teleanu, A. Stenzinger, Christoph Heining, Anna Lena Illert, Sebastian Ochsenreither, I.A. Bhatti, M. Scheytt, Peter Horak, Andreas Mock, L. Heiligenthal, A. Benner, B Hutter, K. Steindorf, J. Hüllein
Publikováno v:
ESMO Open
Background Approvals of cancer therapeutics are primarily disease entity specific. Current molecular diagnostic approaches frequently identify actionable alterations in rare cancers or rare subtypes of common cancers for which the corresponding treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3ab91cc0193c0d751c3d5e20b28709a
https://pubmed.ncbi.nlm.nih.gov/34808524
https://pubmed.ncbi.nlm.nih.gov/34808524